Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00958893 · ClinicalTrials.gov registry record · Phase 2
An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext
A Phase 2 study, sponsored by Repros Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00958893 is a Phase 2 study that was terminated before completion, run by Repros Therapeutics. The registered enrollment target is 4 participants.
The verdict
NCT00958893, a Phase 2 study, was terminated before completion, sponsored by Repros Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
An open label, extension study for subjects completing the ZPU-003 Ext 1 study.
Interventions
- DRUG 25 mg Proellex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00958893
The ClinicalTrials.gov registry entry for NCT00958893 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 25 mg Proellex is the first listed.
NCT00958893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00958893 about?
NCT00958893 is a clinical study titled "An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext". An open label, extension study for subjects completing the ZPU-003 Ext 1 study.
What is the current status of trial NCT00958893?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2008-06. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00958893?
The interventions under investigation include: 25 mg Proellex (DRUG).
Who is sponsoring clinical trial NCT00958893?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.